Patents by Inventor Yoshihisa Yamano

Yoshihisa Yamano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200010553
    Abstract: An object of the present invention is to provide a novel therapeutic or preventive agent for human T cell leukemia virus type-1 associated myelopathy (HAM) containing an anti-human CC-chemokine receptor 4 (CCR4) antibody or an antibody fragment thereof as an active ingredient, and characterized by the administration and dosage of the antibody or the antibody fragment thereof. The present invention relates to a therapeutic or preventative agent for HAM characterized in that an anti-human CCR4 antibody or an antibody fragment thereof is contained as an active ingredient and the antibody or the antibody fragment thereof is administered at a low dose.
    Type: Application
    Filed: March 2, 2018
    Publication date: January 9, 2020
    Applicants: St. Marianna University School of Medicine, KYOWA KIRIN CO., LTD.
    Inventor: Yoshihisa YAMANO
  • Publication number: 20190343816
    Abstract: The present invention provides a pharmaceutical composition containing an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor as an active ingredient, for use in treating HTLV-1-associated myelopathy. The present invention provides a pharmaceutical composition for use in treating HTLV-1-associated myelopathy, containing a 1,3-benzodioxole derivative or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 18, 2018
    Publication date: November 14, 2019
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE
    Inventors: Yoshihisa YAMANO, Natsumi UEDA, Kazushi ARAKI
  • Patent number: 10294302
    Abstract: The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 (also known as human T lymphotropic virus type-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: May 21, 2019
    Assignees: ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE, KYOWA HAKKO KIRIN CO., LTD
    Inventor: Yoshihisa Yamano
  • Publication number: 20170240859
    Abstract: The purpose of the present invention is to provide a method for producing ??T cells with which it is possible to obtain a cell population including a large amount of ??T cells and including virtually no cells infected by human T-cell leukemia virus (HTLV) even when PBMCs derived from a person infected with HTLV are used as the cell source. A cell population including a large amount of ??T cells and including virtually no HTLV-1-infected cells is obtained by culturing after removing CD4-positive cells that express CD4 (referred to hereinafter as “CD4+ cells”) and CD8-positive cells that express CD8 (referred to hereinafter as “CD8+ cells”) from the PBMCs that are used as the cell source, or after removing cells that express ??T cell receptors (??TCR) (referred to hereinafter as “??T cells”), before expanding ??T cells.
    Type: Application
    Filed: October 13, 2015
    Publication date: August 24, 2017
    Inventors: Yoshihisa YAMANO, Ken-ichiro SEINO, Masato MUTO
  • Publication number: 20170204189
    Abstract: The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 (also known as human T lymphotropic virus type-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.
    Type: Application
    Filed: March 31, 2017
    Publication date: July 20, 2017
    Applicants: St. Marianna University School of Medicine, KYOWA HAKKO KIRIN CO., LTD
    Inventor: Yoshihisa YAMANO
  • Patent number: 9642910
    Abstract: The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 (also known as human T lymphotropic virus type-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: May 9, 2017
    Assignees: St. Marianna University School of Medicine, KYOWA HAKKO KIRIN CO., LTD
    Inventor: Yoshihisa Yamano
  • Publication number: 20140037654
    Abstract: The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.
    Type: Application
    Filed: July 8, 2013
    Publication date: February 6, 2014
    Applicants: KYOWA HAKKO KIRIN CO., LTD, St. Marianna University School of Medicine
    Inventor: Yoshihisa YAMANO
  • Publication number: 20130196980
    Abstract: A diagnostic agent and a diagnostic method for appropriately diagnosing fibromyalgia of a specific type, and a therapeutic agent for the aforesaid type include a diagnostic agent for fibromyalgia relating to an anti-voltage-gated potassium channel complex antibody (anti-VGKC complex antibody), said diagnostic agent containing a reagent for detecting the anti-VGKC complex antibody; a diagnostic method using the diagnostic agent; and a therapeutic agent for fibromyalgia relating to the anti-VGKC complex antibody. A diagnostic agent for fibromyalgia relating to an antibody against a voltage-gated potassium channel complex includes a reagent for detecting the antibody against the voltage-gated potassium channel complex; and a therapeutic agent for fibromyalgia relating to an antibody against voltage-gated potassium channel contains an effective amount of an anticonvulsant drug (gabapentine or clonazepam) as the active ingredient.
    Type: Application
    Filed: October 4, 2011
    Publication date: August 1, 2013
    Applicant: AXIS INC.
    Inventors: Yoshihisa Yamano, Kusuki Nishioka
  • Publication number: 20070178532
    Abstract: Methods of quantifying and/or characterizing antigen-specific T cell populations, identifying T cell antigens and epitopes, and preparing targeted pharmaceutical compositions by (i) introducing a peptide into an antigen-presenting cell (APC) expressing a fusion protein comprising a major histocompatibility complex portion and a reporter peptide portion such that a complex forms between the fusion protein and the peptide and the peptide is displayed by the APC and (ii) contacting the APC with a population of cells, such that T cells in the population of cells that react with the peptide detectably internalize the complex; novel APCs useful in such methods; and related therapeutic and diagnostic methods.
    Type: Application
    Filed: March 24, 2004
    Publication date: August 2, 2007
    Applicant: THE GOV.OF THE US AS REPRESENTED BY THE SECRETARY
    Inventors: Steven Jacobson, Utano Takeuchi, Yoshihisa Yamano